“…EC has well characterized signaling actions in neural cells ( Schroeter et al, 2007 ; Bahia et al, 2008 ) and is a promising intervention for AD due to its low toxicity profile ( Ottaviani et al, 2015 ) and potential for multi-modal targeting ( Hole and Williams, 2020 ). EC has been shown to improve vascular function and cognition in humans ( Bernatova, 2018 ; Haskell-Ramsay et al, 2018 ), reduce oxidative stress and up-regulate neuroprotective pathways ( Schroeter et al, 2001 ; Spencer et al, 2001 ; Shah et al, 2010 ; Rendeiro et al, 2013 ; Zhang et al, 2016 ; Navarrete-Yañez et al, 2020 ). With respect to AD pathology, intervention with EC has been shown to inhibit APP processing in primary cortical neurons ( Cox et al, 2015 ) and reduce Aβ burden in APP SWE /PS1 mouse models ( Zeng et al, 2014 ; Cox et al, 2015 ).…”